[Focal laser coagulation in the treatment of a patient with kidney cancer and prostate cancer].

The article describes the clinical observation of the patient 84 years old with prostate cancer T2bNxM0, left kidney cancer T1N0M0 and severe comorbidity. Stepwise interstitial laser coagulation was performed using the Russian microsecond Nd: YAG laser surgical complex.

[Interstitial laser coagulation in the management of urothelial papillary carcinoma of the renal pelvis].

This article presents a case of a 59-year-old patient with a primary tumor of the right kidney with bladder and liver metastases. The patient was treated in three-stages. In the first stage, he underwent ureteral stone extraction, laser resection of the tumor with subsequent vaporization. In the second stage, a repeat laser resection and vaporization of the tumor was performed. During the third stage, the patient underwent TUR of the bladder wall with the tumor, followed by laser vaporization of the tumor bed. During a 9-year follow-up, no signs of tumor growth or metastasis were observed.

Results of the treatment of benign prostatic hyperplasia by ILC Indigo 830e system

Background: Interstitial Laser Coagulation (ILC) Indigo 830e system is the first technique that is used in Viet Nam for the treatment of Benign Prostatic Hyperplasia (BPH) patients. Objectives: (1) To evaluate the effects of treatment of benign prostatic hyperplasia by ILC Indigo 830e system. (2) To describe peri- and post-proceduce complications. Subjects and method: The study consisted of 106 BPH patients who treated by ILC Indigo 830e system. This was a cross-section, descriptive study. Results: Overally, good and moderate outcomes was 94.8%, unsatisfactory was 5.2%. The peri- and post-proceduce complications were: urethral irritability 20.8%, prolonged catheterization 4.7%, urinary tract infections 4.7% and hematuria 0.94%. Conclusion: The treatment for benign prostatic hyperplasia patients by ILC Indigo 830e system was an effective and safe therapy, especially in elderly patient group who had multiple diseases.

The Effects of Interstitial Laser Coagulation on Quality of Life and Sexual Function in Patients with Benign Prostatic Hyperplasia / 대한비뇨기과학회지

PURPOSE: To determine the impact of interstitial laser coagulation (ILC) on the quality of life and sexual function in patients with a benign prostatic hyperplasia (BPH). MATERIALS AND METHODS: Eighty-nine patients treated with ILC were prospectively evaluated. The treatment outcome was evaluated 1, 3, 6 months and 1 year after the ILC with the international prostate symptom score (IPSS), the prostate volume, the peak urinary flow rate (Q-max), the post-void residual urine (PVR), and the quality of life assessment score. In addition, a self-reporting questionnaire including the International Index of Erectile Function (IIEF) were completed before and 3 months after treatment to determine the impact on sexual function. RESULTS: ILC showed significant improvement in the clinical and voiding parameters (IPSS, Q-max, PVR, prostate size). After ILC, 76% of patients were satisfied with the treatment and the quality of life score improved significantly after 3 months. There was no significant difference between the mean scores of the pretreatment and post-treatment erectile function, orgasmic function, sexual desire and intercourse satisfaction. However, the overall satisfaction score decreased from the pre-operative value of 3.05 to a post-operative value of 2.27 (p<0.05). An ejaculation loss or severe decrease in ejaculate volume was reported in 11 (23%) of the 46 patients followed up after ILC. Interestingly, only 5 (45%) of the 11 patients with a loss of ejaculation or severe decrease in ejaculate reported a deterioration of their sex life, while only 1 (4%) of the 23 without any change in ejaculate volume reported such deterioration. CONCLUSIONS: There were no significant changes in sexual desire, erectile function, orgasmic function, and intercourse satisfaction with ILC. However, the overall satisfaction decreased after ILC. Post-treatment sexual dysfunction appears to be mainly related to the impaired ejaculatory function.

Early Clinical Experience of Interstitial Laser Coagulation(ILC) for the Treatment of Benign Prostatic Hyperplasia / 대한비뇨기과학회지

PURPOSE: Variable modalities, with more comfortable and less incidence of post-operative complications over TURP, have been used for the treatment of benign prostatic hyperplasia(BPH) with bladder outlet obstruction. Recently, we performed Interstitial Laser Coagulation(ILC) with the 830nm diode laser, which is considered as a method of minimally invasive treatments for BPH, to assess the efficacy and safety of the device, and to evaluate its capability of replacing TURP for managing BPH. MATERIALS AND METHODS: We analysed 16 patients, who had suffered from symptomatic BPH, treated with ILC using diode laser retrospectively from April 1996 to January 1997. Mean age of the patients was 71.7(52-84) years old and mean size of prostates before the treatments was 52.2(26.8-100.7)gm. Treatment outcome was estimated by comparing IPSS, QOL, Qmax, Qave and residual urine before the operations with them of first and second month after the operations. Post-operative transrectal ultrasonography was able to several cooperative cases and they were compared with them of pre-operative volumes, too, although it was unavailable to evaluate statistically. RESULTS: The operation were performed under epidural or spinal anesthesia with average time of 62 minutes and with 10 days of post-operative catheterization. IPSS reduced from 22.25(+/-4.82), mean value before the operation, to 11.00(+/-5.58) and 5.00(+/-3.10) at first and second month after ILC. QOL was gradually decreased from 4.44(+/-0.51) to 2.31(+/-1.20) and 1.19(+/-0.91), too. In terms of Qmax, mean was 12.29(+/-5.55)ml/sec before the operation and it was increased to 15.94(+/-7.38)ml/sec and 20.75(+/-8.48)ml/sec. Average flow rate was also increased from 6.98(+/-2.05)ml/sec to 10.38(+/-3.72)ml/sec and 14.93(+/-4.37)ml/sec. Significant reduction was observed in residual urine volume from 98.13(+/-91.72)ml to 33.19(+/-36.58)ml and 9.56(+/-11.24)ml respectively. Minimal hematuria and mild bladder irritations were common symptoms after the procedure, and possible significant complications as like anemia, electrolyte imbalance(post-TUR syndrome), epididymoorchitis, erectile dysfunction, urethral stricture, retrograde ejaculation had not found in our experience, but 1 patient was retreated with TURP because of continued bladder outlet obstruction. CONCLUSIONS: Our initial results with ILC showed that it is a relatively simple and minimally invasive method with minimal occurrence of bleeding and no electrolyte imbalance. We concluded that ILC is a safe and efficacious treatment modality, and it can be used even for elder patients with co-morbidity illness as well as patients with too large prostate to perform TURP.